Literature DB >> 23686485

Host B7-H4 regulates antitumor T cell responses through inhibition of myeloid-derived suppressor cells in a 4T1 tumor transplantation model.

Joanne Leung1, Woong-Kyung Suh.   

Abstract

B7-H4, a member of the B7 family of T cell immunomodulatory proteins, has been shown to inhibit T cell responses and neutrophil expansion during bacterial infections. However, the role of B7-H4 in the immune response during tumor growth has been unclear. In this study, we examined the host immune responses in B7-H4-deficient (knockout [KO]) or sufficient (wild-type [WT]) BALB/cJ mice upon transplantation of murine 4T1 carcinoma cells that had little B7-H4 expression. We reveal that host B7-H4 not only dampens the antitumor Th1 responses, but also inhibits the protumor function of myeloid-derived suppressor cells (MDSC). We observed increased expression of both antitumor immune effectors and protumor MDSC-associated transcripts in 4T1 tumors grown in B7-H4 KO mice compared with those grown in WT hosts. Consistently, MDSCs derived from B7-H4 KO mice suppressed T cell proliferation more potently than their WT counterparts. Although the primary growth of 4T1 tumors in B7-H4 KO hosts was similar to that in WT mice, tumors that had grown in B7-H4 KO hosts grew much slower than those from WT mice when subsequently transplanted into WT hosts. Importantly, this differential tumor growth during the secondary transplantation was abrogated when recipient mice lacked T cells, indicating that the immune environment in B7-H4 KO hosts allowed outgrowth of 4T1 tumors with reduced immune-evasive capacities against T cells. Thus, B7-H4 can inhibit both antitumor T cells and protumor MDSCs, influencing the immune-evasive character of the outgrowing tumors. These factors should be considered if B7-H4 blockade is to be used for cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23686485     DOI: 10.4049/jimmunol.1201242

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy.

Authors:  Jenessa B Smith; Evripidis Lanitis; Denarda Dangaj; Elizabeth Buza; Mathilde Poussin; Caitlin Stashwick; Nathalie Scholler; Daniel J Powell
Journal:  Mol Ther       Date:  2016-07-21       Impact factor: 11.454

Review 2.  Potential targeting of B7-H4 for the treatment of cancer.

Authors:  Joseph R Podojil; Stephen D Miller
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

Review 3.  Combination cancer immunotherapies tailored to the tumour microenvironment.

Authors:  Mark J Smyth; Shin Foong Ngiow; Antoni Ribas; Michele W L Teng
Journal:  Nat Rev Clin Oncol       Date:  2015-11-24       Impact factor: 66.675

4.  Construction, expression and functional analysis of anti-B7-H4- scFv-CH3 recombinant antibody.

Authors:  Hongshuai Ji; Jinrui Guo; Ying Yang; Chaochao Xu; Weiping Mao
Journal:  J Biosci       Date:  2018-09       Impact factor: 1.826

Review 5.  Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go.

Authors:  Angela Vasaturo; Stefania Di Blasio; Deborah G A Peeters; Coco C H de Koning; Jolanda M de Vries; Carl G Figdor; Stanleyson V Hato
Journal:  Front Immunol       Date:  2013-12-03       Impact factor: 7.561

Review 6.  The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy.

Authors:  Joanne Leung; Woong-Kyung Suh
Journal:  Immune Netw       Date:  2014-12-22       Impact factor: 6.303

7.  Tumor-expressed immune checkpoint B7x promotes cancer progression and antigen-specific CD8 T cell exhaustion and suppressive innate immune cells.

Authors:  Kim C Ohaegbulam; Weifeng Liu; Hyungjun Jeon; Steven C Almo; Xingxing Zang
Journal:  Oncotarget       Date:  2017-09-20

8.  Extramammary Paget disease shows differential expression of B7 family members B7-H3, B7-H4, PD-L1, PD-L2 and cancer/testis antigens NY-ESO-1 and MAGE-A.

Authors:  Maryam Pourmaleki; Jonathan H Young; Nicholas D Socci; Sarah Chiang; Marcia Edelweiss; Yanyun Li; Mianlei Zhang; Lev Roshal; Dennis S Chi; Klaus J Busam; Ingo K Mellinghoff; Travis J Hollmann
Journal:  Oncotarget       Date:  2019-10-22

9.  STAT3 Silencing and TLR7/8 Pathway Activation Repolarize and Suppress Myeloid-Derived Suppressor Cells From Breast Cancer Patients.

Authors:  Elham Safarzadeh; Ali Mohammadi; Behzad Mansoori; Pascal H G Duijf; Shahryar Hashemzadeh; Vahid Khaze; Tohid Kazemi; Afshin Derakhshani; Nicola Silvestris; Behzad Baradaran
Journal:  Front Immunol       Date:  2021-02-19       Impact factor: 7.561

10.  Serum soluble B7-H4 is a prognostic marker for patients with non-metastatic clear cell renal cell carcinoma.

Authors:  Takeshi Azuma; Yujiro Sato; Tetsukuni Ohno; Miyuki Azuma; Haruki Kume
Journal:  PLoS One       Date:  2018-07-25       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.